Amgen Stock Steady at EUR 358.63 Amid Positive Dazodalibep Results

Amgen's stock price remained steady at EUR 358.63 in weekend trading on October 3, 2026, despite a small increase from its closing value of EUR 358.50 on October 2.

The company reported positive top-line results from the Phase 3 OASIZ 301 study for dazodalibep on September 22, 2026, which showed statistically significant and clinically meaningful improvement in systemic disease activity measured by the EULAR Sjögren's Syndrome Disease Activity Index.

According to Amgen, improvements were observed as early as Week 4 and were sustained through Week 48. The study evaluated adults with Sjögren's disease and moderate-to-severe systemic disease activity.